Published in final edited form as:

Eur J Pharmacol. 2010 October 10; 644(1-3): 80–87. doi:10.1016/j.ejphar.2010.07.008.

Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala

Jamie L. Scholl, Shawn M. Vuong, and Gina L. Forster*

Division of Basic Biomedical Sciences and Neuroscience Group, Sanford School of Medicine, University of South Dakota, 414 E. Clark St. Vermillion, SD, USA.

Abstract

Amphetamine use is associated with dysphoric states, including heightened anxiety, that emerge within 24 h of withdrawal from the drug. Corticotropin-releasing factor increases serotonin release in the central nucleus of the amygdala, and this neurochemical circuitry may play a role in mediating fear and anxiety states. We have previously shown that chronic amphetamine treatment increases corticotropin-releasing factor receptor type-2 levels in the serotonergic dorsal raphe nucleus of the rat. Therefore, we hypothesized that chronic amphetamine treatment would enhance the amygdalar serotonergic response to corticotropin-releasing factor infused into the dorsal raphe nucleus. Male rats were injected once-daily with *d*-amphetamine (2.5 mg/kg i.p., or saline) for two weeks. Serotonin release within the central nucleus of the amygdala in response to intra-raphe infusion of corticotropin-releasing factor (100 ng) was measured 24 h after the last treatment in urethane-anesthetized (1.8 mg/kg, i.p.) rats using *in vivo* microdialysis. Rats pretreated with amphetamine showed significantly enhanced serotonin release in the central nucleus of the amygdala in response to corticotropin-releasing factor infusion when compared to saline pretreated rats. Furthermore, this enhanced response was blocked by the corticotropin-releasing factor type-2 receptor antagonist antisauvagine-30 (2 µg) infused into the dorsal raphe nucleus. These results suggest increased sensitivity to corticotropin-releasing factor as mediated by type-2 receptors following chronic amphetamine treatment, which may underlie dysphoric states observed during amphetamine withdrawal.

Index Words

dorsal raphe nucleus; central nucleus of the amygdala; CRF₂ receptors; rat; microdialysis

1. Introduction

Drug addiction is a chronic disorder that is characterized by a cycle of compulsive use and drug-seeking, and by a withdrawal syndrome that includes negative affective states (Koob, 2008; Koob and Volkow, 2010). In both humans and rat models, withdrawal from psychostimulant use can lead to increased sensitivity to stress, depressive behavior and increased anxiety that emerges within 24 h of drug abstinence (Harris and Aston-Jones, 1993; Sarnyai et al., 1995, 2001; Basso et al., 1999; Barr and Markou, 2005; Sinha et al.,

© 2010 Elsevier B.V. All rights reserved.

*Corresponding Author Gina L. Forster, Ph.D., Division of Basic Biomedical Sciences, Sanford School of Medicine, University of South Dakota, 414 E. Clark St., Vermillion, SD, 57069, USA, Telephone: (605) 677 6883, Fax: (605) 677 6381, gforster@usd.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

2006; Perrine et al., 2008; Vuong et al., 2010). Negative affect and increased sensitivity to stress during drug abstinence appear to promote drug seeking and drug relapse (Sarnyai et al., 2001; Weiss, et al., 2001; Koob, 2003; 2008; Sinha et al., 2006). Therefore, the study of neural stress systems following chronic psychostimulant use may identify neural alterations that underlie dysphoric states during drug withdrawal.

Central corticotropin-releasing factor (CRF) mediates stress-related and anxiety-like behaviors, and also regulates serotonin (5-HT) limbic systems that are involved in stress and anxiety states (Heinrichs et al., 1992; Takahashi, 2001; Bale, 2005; Lowry et al., 2005; Forster et al., 2006; 2008; Lukkes et al., 2009b). The dorsal raphe nucleus (dRN) provides serotonergic innervation to the limbic system including the central nucleus of the amygdala (CeA) (Petrov et al., 1994). Both CRF type 1 and type 2 receptors are found within the dRN (Day et al., 2004; Waselus et al., 2009) and have opposing effects on 5-HT release (Lukkes et al., 2008). Infusion of CRF or CRF-like peptides increase 5-HT release in limbic regions including the CeA, and excitatory CRF responses on 5-HT activity are mediated by CRF₂ receptors in the dRN (Amat et al., 2004; Pernar et al., 2004; Forster et al., 2006; 2008; Lukkes et al., 2008). Furthermore, restraint stress increases 5-HT release in the CeA, which is inhibited by an intracerebroventricular injection of a CRF_{1/2} antagonist (Mo et al., 2008). Increased 5-HT activity in the CeA stimulates release of circulating glucocorticoids via activation of the hypothalamic-pituitary-adrenal axis (Feldman et al., 1998; 2000), and both 5-HT and glucocorticoids in the CeA contribute to anxiety states (Shepard et al., 2000; Myers et al., 2005). Likewise, increased serotonergic tone is believed to be an important mediator of the amygdala hyper-reactivity that is observed in affective disorders (Fisher et al., 2006). Alterations to CRF-5-HT interactions within the amygdala could also be related to dysphoric states during drug withdrawal.

Recently we have found that CRF₂ receptors are increased in the dRN 20 h following chronic amphetamine treatment and remain elevated up to 6 weeks of withdrawal (Pringle et al., 2008). Furthermore, CRF₂ receptor antagonism in the dRN reduces anxiety-like behavior during amphetamine withdrawal (Vuong et al., 2010). Given that CRF₂ receptors in the dRN have excitatory effects on limbic 5-HT release (Amat et al., 2004; Forster et al., 2006; 2008; Lukkes et al., 2008) we hypothesized that that chronic amphetamine treatment enhances CRF-induced 5-HT responses in the CeA via CRF₂ receptors in the dRN.

2. Materials and Methods

2.1 Animals

Male Sprague-Dawley rats (n=56; 3 weeks old) were purchased from the University of South Dakota Animal Resource Center. Rats were pair-housed in a climate-controlled holding room maintained at 22°C, on a reverse 12h light/12 h dark cycle with free access to food and water. Rats were used in the subsequent experiments when they reached early adulthood at 8 weeks old. The following procedures were approved by the Institutional Animal Care and Use Committee of the University of South Dakota, and were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize the use and suffering of animals.

2.2 Experiment 1: Role of dRN-mediated CRF-induced 5-HT increases in the CeA

The first experiments tested whether CRF (100 ng) infused into the dRN of rats that did not receive saline or amphetamine pretreatment (termed “untreated”) would elicit a similar increase in CeA 5-HT release in urethane-anaesthetized rats as we had demonstrated in freely-moving rats (Forster et al., 2006). The use of urethane-anesthetized rats was necessary in subsequent experiments for dual cannula studies to elucidate receptor mechanisms,

similar to procedures we have performed previously in urethane-anaesthetized rats (e.g. Lukkes et al., 2008; Forster et al., 2008). Urethane has minimal effect on neurotransmitter release and neuronal firing rates (Maggi and Meli, 1986), and both baseline and CRF-elicited 5-HT release are similar between freely-moving and urethane-anesthetized rats (Forster et al., 2006; 2008).

2.2.1 Surgery—Eleven rats were anaesthetized with urethane (1.5 g/kg, i.p.) and placed within a small mammal stereotaxic frame (Kopf, Tujunga, CA, USA). Anesthesia (up to 1.8 g/kg, i.p.) was maintained throughout the entire experiment, with body temperature held at 37 °C by a temperature-controlled heating pad (Harvard Apparatus, Holliston, MA, USA). A stainless-steel guide cannula (26 gauge, laboratory-made) was stereotactically implanted so the guide cannula was positioned 2 mm above the dRN (AP: −8.1 mm from bregma, ML: +2.8 mm from midline at a 26° angle lateral to medial; DV: −3.8 mm from dura; Paxinos and Watson, 1998). A microdialysis probe (2.5 mm exposed membrane length, 5000 MW cut-off, typical recovery 20%, laboratory-made; Forster et al., 2006) was directly inserted into the CeA (AP: −2.3 mm from bregma; ML: −4.0 mm from midline; −8.7 mm from dura; Paxinos and Watson, 1998). Following probe insertion, artificial cerebral spinal fluid (aCSF) was perfused through the probe at a rate of 0.4 µl/min via PE20 tubing connected to a 1 ml syringe within a microinfusion pump (Harvard Apparatus).

2.2.2 Microdialysis and dRN Infusion—Silica cannula (197 µm o.d., cut 2mm longer than guide); Polymicro Technologies, Phoenix, AZ, USA) were attached to PE20 tubing and back-loaded with either drug or vehicle and connected to a 10 µl Hamilton syringe. A cannula was inserted into the dRN through the cannula guide 3 h following probe insertion. After 1 h, dialysate samples were collected from the CeA microdialysis probe at 20 min intervals and injected immediately into a high-performance liquid chromatography (HPLC) with electrochemical detection (see details below) to measure 5-HT. Following collection of 3 baseline samples, a 0.5 µl microinfusion of either vehicle (aCSF; n = 4) or CRF (100 ng in aCSF; n = 7) was made into the dRN. All drug infusions were made at a rate of 0.5 µl/min using a microinfusion pump (Stoelting, Wood Dale, IL, USA). Dialysate samples were collected until CeA 5-HT returned to baseline levels, or if no change in 5-HT was detected, 8 post-infusion samples were collected.

2.3 Experiment 2: Effects of amphetamine pretreatment on CRF-induced 5-HT release in the CeA – mediation by CRF₂ receptors in the dRN

These experiments tested whether chronic amphetamine treatment results in increased CRF-induced 5-HT release in the CeA of urethane-anesthetized rats. Given that CRF₂ receptors are up-regulated in amphetamine pretreated rats (Pringle et al., 2008), the role of CRF₂ receptors was assessed by pretreatment of the dRN with the selective CRF₂ receptor antagonist antisauvagine-30 (ASV-30; Lukkes et al., 2008; Forster et al., 2008). This antagonist has 1,000–10,000 fold selectivity for the vertebrate CRF₂ receptor over the CRF₁ receptor (Higelin et al., 2001), and does not affect CRF₁ receptor mediated 5-HT release at this concentration infused into the dRN (2 µg; Lukkes et al., 2008).

2.3.1 Amphetamine Treatment—Using a separate group of rats from Experiment 1, amphetamine (2.5 mg/kg, i.p. n = 31) or saline (n = 14) was injected into each rat once-daily for 14 days during the dark (active) phase of the light cycle. This amphetamine treatment regime produces heightened anxiety states upon withdrawal of the drug (Vuong et al., 2010) and result in increased CRF₂ receptors in the dRN (Pringle et al., 2008). Following injections, rats were returned to their home cage. Rats were anaesthetized for stereotaxic surgery the morning following the last day of injections.

2.3.2 Surgery—Rats were anaesthetized with urethane (1.5 g/kg, i.p.) and placed within a small mammal stereotaxic frame as described in Experiment 1. Stainless steel dual guide cannulae (26 gauge, laboratory-made) were made so that the tips of the guides were adjacent to ensure infusions in the same region of the dRN. The dual guide cannulae were stereotactically implanted so the guides were positioned 2 mm above the dRN (AP: −8.1 mm from bregma, ML: +2.8 mm from midline at a 26° angle lateral to medial; DV: −3.8 mm from dura; Paxinos and Watson, 1998). A microdialysis probe was inserted into the CeA as described in Experiment 1.

2.3.3 Microdialysis and dRN Infusion—Two silica cannulae were inserted into the dRN through the cannula guides 3 h following probe insertion and dialysis samples were collected as described in Experiment 1. Following collection of 3 baseline samples, one of four dual infusions was made into the dRN (as described for Experiment 1) with 10 min separating each infusion (see Table 1 for specific infusions made). The concentration of the CRF₂ receptor antagonist ASV-30 used by the current study completely reverses anxiety states in amphetamine treated rats when infused into the dRN without affecting control rat behavior or general activity (Vuong et al., 2010). The 2% ethanol vehicle for ASV has no effect on 5-HT release (Forster et al., 2008; Lukkes et al., 2008). Furthermore, we have utilized this double dRN infusion procedure in the past and it does not result in infusion damage within the dRN (and see Fig. 1D) (Lukkes et al., 2008; Forster et al., 2008). Dialysate samples were collected until CeA 5-HT returned to baseline levels, or if no change in 5-HT was detected, 8 post-infusion samples were collected.

2.4 HPLC Measurement of 5-HT

Detection of 5-HT in dialysates was accomplished using HPLC with electrochemical detection (Bradberry et al, 1991; Forster et al., 2008). Mobile phase (300 mg EDTA, 432 mg sodium octanesulfonate, 4.8 g NaH₂PO₄, 300 µl triethylamine and 122 ml acetonitrile per liter, pH 5.35); all obtained from Sigma (St. Louis, MO, USA), was pumped through a UniJet 3 µm C₁₈ microbore column (Bioanalytical Systems, West Lafayette, IN, USA) under nitrogen gas pressure (2000 psi). Dialysates were injected onto the chromatographic system using a rheodyne injector via a 5 µl loop (Bioanalytical Systems). The perfusion rate through the probe of 0.4 µl/min resulted in the collection of approximately 8 µl of dialysate/ 20 min to ensure that when the sample was injected into the HPLC, the loop was overfilled. Following separation by the column, 5-HT was detected by a glassy carbon electrode (Bioanalytical Systems), which was maintained at +0.5 V with respect to an Ag/AgCl₂ reference electrode using a LC-4C potentiostat (Bioanalytical Systems). The voltage output was recorded by Clarity v2.4 Chromatography Station for Windows (DataApex, Prague, Czech Republic).

2.5 Histology

Following completion of experiments, rats were killed by overdose with sodium pentobarbital (0.5 ml Fatal Plus, i.p.; Vortech, Dearborn, MI, USA). The brains were removed and fixed in 10% buffered formalin (Fisher Scientific). After fixation, the brains were frozen and sectioned at 60 µm on a microtome; the series of sections encompassing the probe or the cannulae were stained with cresyl violet and were examined under a light microscope by two experimenters that were blind to treatment. Correct placement was determined for both the infusion cannulae and the microdialysis probe.

2.6 Data Analysis

Three baseline samples were collected, and the height of the 5-HT peaks averaged. All post-drug 5-HT peak heights were calculated as a percent change from the average baseline level

for each animal to account for potential variance in 5-HT recovery between microdialysis probes (e.g. Hoffman et al., 2002; Forster et al., 2008; Li et al., 2010; Navailles et al., 2010). For each experiment, the 5-HT levels were analyzed with a two-way ANOVA with one repeated measure (time). A one-way ANOVA was used when there was a significant effect of treatment, to compare the groups at each separate time point. Significant effects of treatment at a given time point were further analyzed by Student-Newman Keul's (SNK) multiple comparison procedure. When a significant effect of time was noted, a one-way ANOVA with one repeated measure was performed across time for each given treatment. Significant time points were then identified by Dunnett's *post-hoc* test for multiple comparisons, where the sample collected immediately prior to the first drug infusion served as the control sample.

2.7 Drugs

Amphetamine, urethane, corticotropin-releasing factor (CRF) and antisauvagine-30 trifluoroacetate salt (ASV-30) were purchased from Sigma. CRF was dissolved in aCSF (pH 7.4) and amphetamine was dissolved in sterile physiological (0.9%) saline. Urethane was dissolved in nanopure water to a concentration of 0.345 g/ml, whereas ASV-30 was dissolved in a 2% ethanol / aCSF vehicle (Forster et al., 2008).

3. Results

3.1 Experiment 1: Role of dRN-mediated CRF-induced 5-HT increases in the CeA

Microdialysis probe membranes were located within the CeA from -2.12 to -3.3 mm posterior from bregma (Paxinos and Watson, 1998) (Fig. 1A). The tips of the dRN cannula were located between -7.64 to -8.72 mm posterior from bregma (Paxinos and Watson, 1998) with the majority of the infusions made at -8.0 from bregma (Fig. 1A). Drug infusions were made on an angle to avoid the cerebral aqueduct and we have previously demonstrated that infusion of $0.5 \mu\text{l}$ CRF on this angle provides a specific infusion to the dRN without functional diffusion to the ventricle or surrounding periaqueductal gray (e.g. Forster et al., 2006; 2008; Lukkes et al., 2008; and see Fig. 4).

Serotonin peaks were identified by comparison to a 5-HT standard ($7.9 \text{ pg}/5 \mu\text{l}$ 5-HT). The 2:1 signal to noise detection limit for 5-HT using this system was $0.09 \pm 0.01 \text{ pg}$, and the mean $\pm$ S.E.M. baseline level of CeA 5-HT for untreated rats was $0.31 \pm 0.04 \text{ pg}/5 \mu\text{l}$, for amphetamine treated rats was $0.57 \pm 0.16 \text{ pg}/5 \mu\text{l}$, and for saline treated rats was $0.32 \pm 0.05 \text{ pg}/5 \mu\text{l}$ (uncorrected for recovery). There was no statistical difference in baseline levels between the three groups ($F_{(2,42)} = 0.980$, $P = 0.384$). Furthermore, these 5-HT baseline values are in line with those obtained from the CeA of awake rats $0.32 \pm 0.11 \text{ pg}/5 \mu\text{l}$ (e.g. Mo et al., 2008).

Infusion of CRF ($100 \text{ ng}/0.5 \mu\text{l}$) into the dRN resulted in an immediate and transient increase in CeA 5-HT in rats that were not previously treated with amphetamine or saline (Fig. 2). There was a significant effect of treatment ($F_{(1,9)} = 8.930$, $P = 0.015$) as well as a significant effect of time ($F_{(11,91)} = 2.022$, $P = 0.035$) but no significant interaction between treatment and time ($F_{(11,91)} = 1.340$, $P = 0.216$, Fig. 2). Infusion of CRF into the dRN caused an increase in CeA 5-HT at 20 min (SNK, $P < 0.001$) and 40 min (SNK, $P = 0.050$) post-infusion compared to infusion of vehicle. Separate one-way ANOVA showed that rats receiving a microinfusion of CRF exhibited a significant increase in CeA 5-HT over time ($F_{(11,61)} = 2.514$; $P = 0.011$, Fig 2). Serotonin levels were significantly different from pre-infusion levels at 20 min post-infusion (Dunnett's, $P < 0.05$). Rats receiving a microinfusion of vehicle into the dRN exhibited a significant change in CeA 5-HT over time ($F_{(11,30)} =$

2.701; $P = 0.015$) at 120 and 160 min post-infusion (Dunnett's, $P < 0.05$, Fig 2), representing a slight decline in 5-HT levels over the testing period.

3.2 Experiment 2: Effects of amphetamine pretreatment on dRN-mediated CRF-induced 5-HT release in the CeA – mediation by CRF₂ receptors in the dRN

Microdialysis probe membranes were located within the CeA from -2.56 to 3.3 mm posterior from bregma for saline pretreated rats (Paxinos and Watson, 1998) (Fig. 1B). The tips of the dRN cannula for saline pretreated rats were located between -6.72 and -8.3 mm posterior from bregma (Paxinos and Watson, 1998) with the majority of the infusions made at -8.0 from bregma (Fig. 1B). Similarly, microdialysis probe membranes in amphetamine pretreated rats were located within the CeA from -1.6 to -3.3 mm posterior from bregma (Fig. 1C) and the tips of the dRN cannula for amphetamine pretreated rats were located between -6.72 and -8.72 mm posterior from bregma (Fig. 1C). The distribution of microdialysis probes and drug cannulae were similar for the different pharmacological treatment groups. Representative stained sections of probe membrane and drug cannula tracks are depicted in Fig. 1D.

Infusion of CRF (100 ng/0.5 μ l) to the dRN resulted in a transient increase in 5-HT release in the CeA in rats pretreated with amphetamine (2.5 mg/kg, i.p.) but not saline (Fig 3A). There was a significant effect of time ($F_{(11,117)} = 3.583$; $P < 0.001$) and a significant interaction between pretreatment and time ($F_{(11,117)} = 4.805$; $P < 0.001$), but no significant effect of pretreatment alone ($F_{(1,12)} = 3.792$, $P = 0.075$) on CeA 5-HT levels. Corticotropin-releasing factor infused into the dRN of amphetamine pretreated rats caused an increase in CeA 5-HT levels which was significant at 20 and 40 min post-infusion compared to saline pretreated rats receiving CRF into the dRN (SNK, $P < 0.001$ at 20 min and $P = 0.015$ at 40 min). Separate one-way ANOVA showed that amphetamine pretreated rats receiving a microinfusion of CRF exhibited a significant increase in CeA 5-HT over time ($F_{(11,69)} = 8.667$; $P < 0.001$, Fig 3A), which was significant at 20 and 40 min post-infusion (Dunnett's, $P < 0.05$ for each time point), compared to pre-infusion levels. Rats pretreated with saline receiving microinfusions of CRF exhibited no significant effect over time ($F_{(5,48)} = 0.468$; $P = 0.914$, Fig 3A).

Infusion of vehicle (aCSF, 0.5 μ l) into the dRN of rats pretreated with amphetamine (2.5 mg/kg, i.p.) or saline had no effect on 5-HT levels in the CeA (Fig. 3B), suggesting that the 2% ethanol vehicle did not alter 5-HT release. For vehicle-infused rats, there was no significant between pretreatment group ($F_{(1,10)} = 0.0536$, $P = 0.822$), across time ($F_{(11,101)} = 0.893$, $P = 0.550$) nor was there a significant interaction between pretreatment and time ($F_{(11,101)} = 0.311$, $P = 0.982$; Fig. 3B).

Infusion of CRF (100 ng/0.5 μ l) outside but adjacent to the dRN (Fig. 1B–C; $n = 6$) in rats previously treated with amphetamine or saline had no effect on CRF-induced 5-HT release in the CeA (Fig. 4). Serotonin levels in the CeA of rats pretreated with amphetamine (2.5 mg/kg, i.p.) or saline were not significantly different between pretreatment group ($F_{(1,4)} = 0.0849$, $P = 0.785$) or across time ($F_{(11,39)} = 0.974$, $P = 0.486$) nor was there a significant interaction between pretreatment and time ($F_{(11,39)} = 0.194$, $P = 0.997$; Fig. 4) when CRF was infused adjacent to the dRN.

In order to confirm that the augmented CRF-induced 5-HT release in the CeA of amphetamine pretreated rats was mediated by CRF₂ receptors in the dRN, the selective CRF₂ receptor antagonist ASV-30 was infused into the dRN prior to CRF or vehicle infusion (Table 1). Infusion of ASV-30 (2 μ g/0.5 μ l) into the dRN 10 min prior to an infusion of CRF (100 ng/0.5 μ l) into the dRN of amphetamine pretreated (2.5 mg/kg, i.p.) rats blocked the effect of CRF on 5-HT release in the CeA (Fig. 5). This was revealed by no

significant effect of infusion ($F_{(1,12)} = 0.0651$, $P = 0.803$) or time ($F_{(11,119)} = 1.216$, $P = 0.284$) nor was there a significant interaction between infusion and time ($F_{(11,119)} = 0.742$, $P = 0.697$; Fig. 5) on 5-HT levels in the CeA of amphetamine pretreated rats when ASV-30 was infused into the dRN prior to CRF or vehicle (aCSF).

4. Discussion

Microinfusion of 100 ng of CRF into the dRN of untreated (no saline or amphetamine pretreatment) urethane-anesthetized rats produced an immediate and transient increase in CeA 5-HT release. This effect (maximum increase at 20 min post-infusion) on 5-HT release shown here is similar to the effect found in freely-moving rats also treated with a higher (500 ng) concentration of CRF (Forster et al., 2006). The effects of CRF in the dRN on CeA 5-HT release are also similar to those elicited by restraint stress, which is also known to be CRF dependent (Mo et al., 2008). Thus, while the levels of stress-induced or amphetamine-induced CRF in the dRN are not known, 100–500 ng of CRF infused into the dRN appears to produce a similar effect on 5-HT as stress. Furthermore, given the similar pattern and time-course of CRF-elicited effects on 5-HT release in the CeA between anesthetized and non-anesthetized rats, the use of anesthetized rats can serve as a useful protocol to examine the mechanisms underlying CRF-mediation of CeA 5-HT release, as we have demonstrated earlier for other limbic brain regions (e.g. Forster et al., 2008; Lukkes et al., 2008).

It has been previously shown that CRF infused into the dRN of anesthetized rats can alter 5-HT neuronal firing rates and 5-HT release in a biphasic fashion (Price et al., 1998; Kirby et al., 2000; Pernar et al., 2004; Lukkes et al., 2008). To illustrate, Lukkes et al (2008) demonstrated that a 100 ng infusion of CRF decreased 5-HT release in the nucleus accumbens (NAc) via CRF₁ receptor activation, where a 500 ng infusion resulted in increased NAc 5-HT release via CRF₂ receptor activation. However, the current findings show that 100 ng CRF infused into the dRN of urethane-anesthetized rats, using methods identical to that of Lukkes et al (2008), actually results in increased 5-HT release in the CeA, as mediated by CRF₂ receptors. The disparate effects are possibly due to differing weighting of CRF₁ and CRF₂ receptor actions on output neurons to the NAc verses the CeA, with CRF₂ receptors perhaps playing a greater role in mediating the activity of neurons projecting to the CeA. A similar hypothesis has been suggested for 5-HT activity in the medial prefrontal cortex, which like the CeA, appears to be predominantly mediated by CRF₂ receptors in the dRN (Forster et al., 2008). While a small number of serotonergic neurons in the dRN send axon collaterals to these regions, the majority do not (van Bockstaele et al., 1993). This raises the interesting possibility that pharmacological differences between the NAc and CeA/ medial prefrontal cortex may arise from differential distribution of CRF receptor types in non-collateral dRN neurons or in dRN interneurons that influence these projection neurons.

In the current study rats were pretreated with an amphetamine treatment schedule that increases anxiety states and increased CRF₂ but not CRF₁ receptors in the dRN (Pringle et al., 2008; Vuong et al., 2010). Here we show that these rats also exhibit sensitized CRF-induced 5-HT release in the CeA, which was mediated by CRF₂ receptors in the dRN. Thus, the increased levels of CRF₂ receptors in the dRN following chronic amphetamine treatment (Pringle et al., 2008) appear to have functional consequences on 5-HT release, and this effect may not be specific to the CeA given the vast 5-HT projections from the dRN to the limbic brain. Related, Waselus et al. (2009) showed that a swim stressor, which increased trafficking of CRF₂ receptors to the neuronal membrane in the dRN, also increased the excitability of dRN 5-HT neurons. Furthermore, post-weaning social isolation of rats which results in heightened anxiety states and increased CRF₂ receptors in the dRN also results in prolonged CRF-mediated 5-HT release in the NAc (Lukkes et al., 2009a). Thus, there may

be common consequences of stressors and long-term amphetamine treatment on CRF-5-HT interactions within the brain.

Activation of CRF₂ receptors in the dRN is thought to increase 5-HT activity and 5-HT release via inhibition of GABAergic input to dRN 5-HT neurons, effectively disinhibiting 5-HT neuronal activity (Pernar et al., 2006). While sensitized CRF-induced 5-HT release in amphetamine pre-treated rats is mediated by CRF₂ receptors, alterations to GABAergic function in the dRN could underlie this observation. Therefore, it would be important to determine whether chronic amphetamine treatment reduces GABAergic inhibition of 5-HT neurons in the dRN, which would then facilitate CRF₂-induced disinhibition of 5-HT neuronal activity and increase 5-HT release.

Recently, we have demonstrated the CRF₂ receptor antagonist ASV-30 infused into the dRN, at the same dose as used here, reduces heightened anxiety-like behaviors of amphetamine pretreated rats to control rat levels (Vuong et al., 2010). The effect of ASV-30 in the dRN on anxiety-like behaviors may be related to our current finding that this antagonist abolishes heightened CRF-induced 5-HT responses in the CeA. Mediation of increased anxiety behavior has been linked specifically to the CRF₂ receptor, with antagonism of CRF₂ receptors decreasing anxiety-like behavior in several animal models of anxiety (Takahashi et al., 2001). Importantly, CRF-induced 5-HT release in the CeA is correlated with the induction in fear behavior (Forster et al., 2006) and restraint stress also increases 5-HT release in the CeA via central CRF receptor mechanisms (Mo et al., 2008). Furthermore, inactivation of the CeA results in an anxiolytic-like effect on the elevated plus maze (Moreira et al., 2007), suggesting a relationship between the CeA and anxiety/fear behavior. In addition, increased extracellular 5-HT levels elicited by acute administration of selective serotonin reuptake inhibitors are associated with increased anxiety states in both humans and animal models (Handley and McBlane et al, 1993; File et al., 1999; Amsterdam et al, 1994; Artaiz et al., 1998; Katzman, 2009). Therefore, future work should test whether the augmented CRF-elicited 5-HT activity in the CeA of amphetamine pretreated rats is directly related to heightened anxiety states.

Interestingly, saline pretreated rats exhibited no change in CRF-induced 5-HT release in the CeA, which was in contrast to rats that did not receive any injection pretreatment, who exhibited increased CRF-induced 5-HT release in the CeA. This suggests that the mild stressor of injections/handling prior to CRF infusion may have dampened the CeA serotonergic response to CRF, and this will require confirmation with dose-response studies. A blunted response of CeA 5-HT has been shown in response to restraint stress, where exposure to experimental manipulations (intracerebroventricular injections) prior to a stressor also dampened CRF-mediated stress-induced 5-HT release in the CeA (Mo et al., 2008). Related, repeated exposure to mild predictable stressors reduces anxiety-like and depressive-like behaviors while increasing hippocampus function (Parihar et al., 2010). Therefore while speculative at this stage, dampened CRF-induced 5-HT release in the CeA following chronic saline treatment may reflect an adaptation to mild stressors, which is absent in amphetamine pretreated rats.

Overall, our results show that chronic amphetamine treatment heightens CeA serotonergic responses to CRF via CRF₂ receptors in the dRN. These finding may explain, in part, increased stress sensitivity and dysphoric states during psychostimulant withdrawal (e.g. Sarnyai et al., 1995; 2001; Koob et al., 2008; Shoptaw, 2009; Vuong et al., 2010). Interestingly, CRF₁ rather than CRF₂ receptors have more often been implicated in stress- and ethanol- or opiate-induced dysphoric states (e.g. Liebich et al., 1995; Bale, 2005; Koob et al., 2009). With relation to stress-induced anxiety states, findings by Henry et al. (2006) suggest that CRF₂ receptors may play a greater role in mediating anxiety states when

animals have been exposed to prior stressors. Recently, CRF₁ receptors in the dRN have been implicated in CRF- and stress-induced sensitization of ethanol-induced anxiety behaviors in rats, with CRF₂ receptors in the dRN appearing to play little role in this anxiety state (Huang et al., 2010). Therefore, anxiety states following ethanol administration appear to be mediated by different CRF receptor mechanisms in the dRN as compared to amphetamine treatment. While our study shows that infusion of a selective CRF₂ receptor antagonist to the dRN completely blocks sensitized CRF-induced release of 5-HT in the CeA in amphetamine pretreated rats, a potential role for CRF₁ receptors cannot be ruled out and should be investigated in the future. Furthermore, the relationship between 5-HT activity in the CeA and dysphoric states during amphetamine withdrawal should be explored, in addition to the possible use of the CRF₂ receptor antagonists to alleviate psychostimulant withdrawal symptoms.

Acknowledgments

This work was supported by grants NIH R01 DA019921 & NIH P20 RR015567 which is a designated Center of Biomedical Research Excellence (COBRE). S.V. was supported by a University of South Dakota Undergraduate Research Award. We thank Dr. Kenneth Renner and Jeffrey Barr for valuable technical assistance and advice regarding these experiments.

References

- Amat J, Tamblyn JP, Paul ED, Bland ST, Amat P, Foster AC, Watkins LR, Maier SF. Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. *Neuroscience*. 2004; 129:509–519. [PubMed: 15541873]
- Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. *J Clin Psychiatry*. 1994; 55:394–400. [PubMed: 7929020]
- Artaiz I, Zazpe A, Del Rio J. Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice. *Behavioural Pharmacol*. 1998; 9:103–112.
- Bale TL. Sensitivity to stress: dysregulation of CRF pathways and disease development. *Horm. Behav*. 2005; 48:1–10. [PubMed: 15919381]
- Barr AM, Markou A. Psychostimulant withdrawal as an inducing condition in animal models of depression. *Neurosci. Biobehav. Rev*. 2005; 29:675–706. [PubMed: 15893821]
- Basso AM, Spina M, Rivier J, Vale W, Koob GF. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. *Psychopharmacology (Berl)*. 1999; 145:21–30. [PubMed: 10445369]
- Bradberry CW, Sprouse JS, Aghajanian GK, Roth RH. Sub-picogram determination of serotonin using HPLC with electrochemical detection for microdialysis studies of serotonin release. *Adv. Exp. Med. Biol*. 1991; 294:81–89. [PubMed: 1685295]
- Day HE, Greenwood BN, Hammack SE, Watkins LR, Fleshner M, Maier SF, Campeau S. Differential expression of 5HT-1A, alpha 1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, gamma-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. *J. Comp. Neurol*. 2004; 474:364–378. [PubMed: 15174080]
- Feldman S, Newman ME, Weidenfeld J. Effects of adrenergic and serotonergic agonists in the amygdala on the hypothalamo-pituitary-adrenocortical axis. *Brain Res. Bull*. 2000; 52:531–536. [PubMed: 10974493]
- Feldman S, Weidenfeld J. The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41. *Brain Res. Bull*. 1998; 45:389–393. [PubMed: 9527013]

- File SE, Ouagazzal A-M, Gonzalez LE, Overstreet DH. Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT_{1A} receptor function. *Pharmacol. Biochem. Behav.* 1999; 62:695–701. [PubMed: 10208375]
- Fisher PM, Meltzer CC, Ziolk SK, Price JC, Moses-Kolko EL, Berga SL, Hariri AR. Capacity for 5-HT_{1A}-mediated autoregulation predicts amygdala reactivity. *Nat. Neurosci.* 2006; 9:1362–1363. [PubMed: 17013380]
- Forster GL, Feng N, Watt MJ, Korzan WJ, Mouw NJ, Summers CH, Renner KJ. Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. *Neuroscience.* 2006; 141:1047–1055. [PubMed: 16713119]
- Forster GL, Pringle RB, Mouw NJ, Vuong SM, Watt MJ, Burke AR, Lowry CA, Summers CH, Renner KJ. Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. *Eur. J. Neurosci.* 2008; 28:299–310. [PubMed: 18702701]
- Harris GC, Aston-Jones G. Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine- and morphine-dependent rats. *Psychopharmacology (Berl).* 1993; 113:131–136. [PubMed: 7862819]
- Handley SL, McBlane JW. 5HT drugs in animal models of anxiety. *Psychopharmacology.* 1993; 112:13–20. [PubMed: 7871002]
- Heinrichs SC, Pich EM, Miczek KA, Britton KT, Koob GF. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. *Brain Res.* 1992; 581:190–197. [PubMed: 1327398]
- Henry B, Vale W, Markou A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. *J. Neurosci.* 2006; 26:9142–9152. [PubMed: 16957071]
- Higelin J, Py-Lang G, Paternoser C, Ellis GJ, Patel A, Dautzenberg FM. I-antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. *Neuropharmacol.* 2001; 40:114–122.
- Hoffman CS, Westin TM, Miner HM, Johnson PL, Summers CH, Renner KJ. GABAergic drugs alter hypothalamic serotonin release and lordosis in estrogen-primed rats. *Brain Res.* 2002; 946:96–103. [PubMed: 12133599]
- Huang MM, Overstreet DH, Knapp DJ, Angel R, Wills TA, Navarro M, Rivier J, Vale W, Breese GR. Corticotropin-releasing factor (CRF) sensitization of ethanol withdrawal-induced anxiety-like behavior is brain site specific and mediated by CRF-1 receptors: relation to stress-induced sensitization. *J. Pharmacol. Exp. Ther.* 2010; 332:298–307. [PubMed: 19843974]
- Katzman MA. Current considerations in the treatment of generalized anxiety disorder. *CNS Drugs.* 2009; 23:103–120. [PubMed: 19173371]
- Kirby LG, Rice KC, Valentino RJ. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. *Neuropsychopharmacol.* 2000; 22:148–162.
- Koob GF. Neuroadaptive mechanisms of addiction: studies on the extended amygdala. *Eur. Neuropsychopharmacol.* 2003; 13:442–452. [PubMed: 14636960]
- Koob GF. A role for brain stress systems in addiction. *Neuron.* 2008; 59:11–34. [PubMed: 18614026]
- Koob GF. Brain stress systems in the amygdala and addiction. *Brain Res.* 2009; 1293:61–75. [PubMed: 19332030]
- Koob GF, Volkow ND. Neurocircuitry of addiction. *Neuropsychopharmacology.* 2010; 35:217–238. [PubMed: 19710631]
- Liebsch G, Landgraf R, Gerstberger R, Probst JC, Wotjak CT, Engelmann M, Holsboer F, Montkowski A. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. *Regulatory Peptides.* 1995; 59:229–239. [PubMed: 8584759]
- Li H, Li C, Yan Z, Yang J, Chen H. Simultaneous monitoring multiple neurotransmitters and neuromodulators during cerebral ischemia/reperfusion in rats by microdialysis and capillary electrophoresis. *J. Neurosci. Meth.* 2010 in press.
- Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J, Shekhar A. Modulation of anxiety circuits by serotonergic systems. *Stress.* 2005; 8:233–246. [PubMed: 16423712]

- Lukkes JL, Forster GL, Renner KJ, Summers CH. Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. *Eur. J. Pharmacol.* 2008; 578:185–193. [PubMed: 17945210]
- Lukkes JL, Summers CH, Scholl JL, Renner KJ, Forster GL. Early life social isolation alters corticotropin-releasing factor responses in adult rats. *Neuroscience*. 2009a; 158:845–855. [PubMed: 19010398]
- Lukkes JL, Watt MJ, Lowry CA, Forster GL. Consequences of post-weaning social isolation on behavior and monoaminergic activity in anxiety-related neural circuits in rats. *Front. Behav. Neurosci.* 2009b; 3:1–12.
- Maggi CA, Meli A. Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 1: general considerations. *Experientia*. 1986; 42:109–114. [PubMed: 2868911]
- Mo B, Feng N, Renner K, Forster G. Restraint stress increases serotonin release in the central nucleus of the amygdala via activation of corticotropin-releasing factor receptors. *Brain Res. Bull.* 2008; 76:493–498. [PubMed: 18534257]
- Moreira CM, Masson S, Carvalho MC, Brandao ML. Exploratory behaviour of rats in the elevated plus-maze is differentially sensitive to inactivation of the basolateral and central amygdaloid nuclei. *Brain Res. Bull.* 2007; 71:466–474. [PubMed: 17259015]
- Myers DA, Gibson M, Schulkin J, Greenwood Van-Meerveld B. Corticosterone implants to the amygdala and type 1 CRH receptor regulation: effects on behavior and colonic sensitivity. *Behav. Brain Res.* 2005; 161:39–44. [PubMed: 15904708]
- Navailles S, Benazzouz A, Bioulac B, Gross C, De Deurwaerdere P. High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit *in vivo* serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. *J Neurosci.* 2010; 30:2356–2364. [PubMed: 20147561]
- Parihar VK, Hattiangady B, Kuruba R, Shuai B, Shetty AK. Predictable chronic mild stress improves mood, hippocampal neurogenesis and memory. *Molecular Psychiatry*. 2010 in press.
- Paxinos, G.; Watson, C. *Stereotaxic Coordinates*. 4th Ed.. San Diego: Academic Press; 1998. The Rat Brain.
- Pernar L, Curtis AL, Vale WW, Rivier JE, Valentino RJ. Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions. *J. Neurosci.* 2004; 24:1305–1311. [PubMed: 14960601]
- Perrine SA, Sheikh IS, Nwaneshiudu CA, Schroeder JA, Unterwald EM. Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat. *Neuropharmacology*. 2008; 54:355–364. [PubMed: 18045627]
- Petrov T, Krukoff TL, Jhamandas JH. Chemically defined collateral projections from the pons to the central nucleus of the amygdala and hypothalamic paraventricular nucleus in the rat. *Cell Tissue Res.* 1994; 277:289–295. [PubMed: 7521791]
- Price ML, Curtis AL, Kirby JG, Valentino RJ, Lucki I. Effects of corticotropin-releasing factor on brain serotonergic activity. *Neuropsychopharmacol.* 1998; 18:492–502.
- Pringle RB, Mouw NJ, Lukkes JL, Forster GL. Amphetamine treatment increases corticotropin-releasing factor receptors in the dorsal raphe nucleus. *Neurosci. Res.* 2008; 62:62–65. [PubMed: 18585412]
- Samyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. *Brain Res.* 1995; 675:89–97. [PubMed: 7796157]
- Samyai Z, Shaham Y, Heinrichs SC. The role of corticotropin-releasing factor in drug addiction. *Pharmacol. Rev.* 2001; 53:209–243. [PubMed: 11356984]
- Shepard JD, Barron KW, Myers DA. Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior. *Brain Res.* 2000; 861:288–295. [PubMed: 10760490]
- Shoptaw SJ, Kao U, Heinzerling K, Ling W. Treatment for amphetamine withdrawal. *Cochrane Database Syst. Rev.* 2009 CD003021.

- Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. *Arch. Gen. Psychiatry*. 2006; 63:324–331. [PubMed: 16520439]
- Takahashi LK. Role of CRF(1) and CRF(2) receptors in fear and anxiety. *Neurosci. Biobehav. Rev.* 2001; 25:627–636. [PubMed: 11801288]
- Takahashi LK, Ho SP, Livanov V, Graciani N, Arneric SP. Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. *Brain Res.* 2001; 902:135–142. [PubMed: 11384606]
- Van Bockstaele EJ, Biswas A, Pickel VM. Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. *Brain Res.* 1993; 624:188–198. [PubMed: 8252391]
- Vuong SM, Oliver HA, Scholl JL, Oliver KM, Forster GL. Increased anxiety-like behavior of rats during amphetamine withdrawal is reversed by CRF-2 receptor antagonism. *Behav. Brain. Res.* 2010 in press.
- Waselus M, Nazzaro C, Valentino RJ, Van Bockstaele EJ. Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. *Biol. Psychiatry*. 2009; 66:76–83. [PubMed: 19362706]
- Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. *Ann. N. Y. Acad. Sci.* 2001; 937:1–26. [PubMed: 11458532]

Fig. 1. Representative coronal diagrams for microdialysis probe and drug infusion cannula placements

Microdialysis probe membrane placement (black bars) in the central nucleus of the amygdala (CeA) and location of drug infusion cannula tips in the dorsal raphe nucleus (dRN; black circles) and cannula tip placements outside the dRN (black stars) of (A) untreated rats, (B) saline pretreated rats and (C) amphetamine pretreated rats. (D) Representative stained sections of CeA microdialysis probe placement and dRN cannula tip placement. Figs were adapted from Paxinos and Watson (1998).

Fig. 2. Effects of corticotropin-releasing factor in the dorsal raphe nucleus on serotonin release in the central nucleus of the amygdala in rats with no previous amphetamine/saline exposure
Corticotropin-releasing factor (CRF; 100 ng/0.5 μ l) infused into the dorsal raphe nucleus resulted in an immediate and transient increase in serotonin release in the central nucleus of the amygdala (CeA). Vehicle (aCSF, 0.5 μ l) infused into the dRN had no effect on serotonin in the CeA. Data represent mean $\pm$ S.E.M. # = significantly different from pre-infusion levels, * = significant differences between treatment groups, $p < 0.05$. Arrow represents time of dRN infusion.

Fig. 3. Effects of corticotropin-releasing factor in the dorsal raphe nucleus on serotonin release in the central nucleus of the amygdala in amphetamine and saline pretreated rats
(A) Corticotropin-releasing factor (CRF; 100 ng/0.5 μ l) infused into the dorsal raphe nucleus of rats previously treated with amphetamine (2.5 mg/kg, i.p.) caused an immediate and transient increase in serotonin release in the central nucleus of the amygdala (CeA), but had no effect on rats previously treated with saline. **(B)** Vehicle (aCSF, 0.5 μ l) infused into the dRN had no effect on serotonin release in the CeA in either pretreatment group. Data represent mean $\pm$ S.E.M. # = significantly different from pre-infusion levels, * = significant differences between treatment groups, $p < 0.05$. Arrows indicate time of infusion, 1 = vehicle for ASV-30 and 2 = CRF (A) or aCSF (B).

Fig. 4. Effects of corticotropin-releasing factor outside the dorsal raphe nucleus on serotonin release in the central nucleus of the amygdala in amphetamine and saline pretreated rats
Corticotropin-releasing factor (CRF 100 ng/0.5 μ l) infused outside but adjacent to the dorsal raphe nucleus of rats previously treated with amphetamine (2.5 mg/kg, i.p.) or saline had no effect on the release of serotonin in central nucleus of the amygdala (CeA). Data represent mean $\pm$ S.E.M. # = significantly different from pre-infusion levels. Arrows indicate time of infusion, 1 = vehicle for ASV-30 and 2 = CRF.

Fig. 5. Effects of corticotropin-releasing factor receptor 2 antagonism in the dorsal raphe nucleus on corticotropin-releasing factor elicited serotonin release in the central nucleus of the amygdala in amphetamine pretreated rats

Pre-infusion of the dorsal raphe nucleus (dRN) with the corticotropin-releasing factor (CRF) receptor 2 antagonist antisauvagine-30 (ASV-30, 2 μ g/0.5 μ l) blocked the stimulatory effect of intra-dRN CRF (100 ng/0.5 μ l) on central nucleus of the amygdala (CeA) serotonin levels in rats previously exposed to amphetamine (2.5 mg/kg, i.p.). Data represent mean $\pm$ S.E.M. Arrows indicate time of infusion, 1 = ASV-30 and 2 = CRF or aCSF (vehicle). Dashed line represents the positive control for this study (vehicle followed by CRF infusion into the dRN of amphetamine pretreated rats) previously shown in Fig. 3A and plotted here to illustrate the impact of ASV-30 on this CRF-induced response.

Table 1

Design of Amphetamine Pretreatment Experiments

Pretreatment	Dorsal raphe pre-infusion	Dorsal raphe infusion	N	Figure
Amphetamine	Vehicle (2% ethanol / aCSF)	CRF (100 ng/0.5 μ l)	8	3A
Saline	Vehicle (2% ethanol / aCSF)	CRF (100 ng/0.5 μ l)	6	3A
Amphetamine	Vehicle (2% ethanol / aCSF)	Vehicle (aCSF)	5	3B
Saline	Vehicle (2% ethanol / aCSF)	Vehicle (aCSF)	6	3B
Amphetamine	ASV-30 (2 μ g/0.5 μ l)	Vehicle (aCSF)	7	5
Amphetamine	ASV-30 (2 μ g/0.5 μ l)	CRF (100 ng/0.5 μ l)	7	5